Publication | Closed Access

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Molecular PharmacologySelective Ppar-δ AgonistHepatologyBiliary TractMedicineGastrointestinal PharmacologyGastroenterologyBiliary DisorderPharmacotherapyPrimary Biliary CirrhosisCholangiopathiesPhase 2PharmacologyInadequate Response